

ACell enters distribution agreement for wound management

20 March 2019 | News | By Manbeena Chawla

MyungMoon will work with ACell to obtain local regulatory clearance.



ACell, Inc. a leading regenerative medicine company, has recently announced that it has entered into an exclusive distribution agreement with MyungMoon Bio Co. Ltd. MyungMoon is a leading manufacturer and distributor of medical devices and pharmaceutical products in South Korea.

The terms of the distribution agreement grant exclusive rights to MyungMoon for the sale, marketing, and distribution of ACell's MicroMatrix® and Cytal® Wound Matrix devices in South Korea. MyungMoon will work with ACell to obtain local regulatory clearance.

"South Korea is one of the largest healthcare markets in the Asia Pacific, and this agreement will meet a growing unmet need for innovative wound management solutions in the country," said Nino Pionati, ACell Vice President, International and Business Development. "We are excited about this partnership, and the opportunity to bring ACell's regenerative products to the patients and clinicians of South Korea."